Precision BioSciences Moves Higher After Commencing Dosing In PBCAR269A Combination Arm Of Multiple Myeloma TrialBenzinga • 06/28/21
Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple MyelomaBusiness Wire • 06/28/21
Precision BioSciences Reports Progress on Two Strategies Designed to Optimize Durability of Allogeneic CAR T Therapy in R/R Non-Hodgkin LymphomaBusiness Wire • 06/04/21
Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In VivoBusiness Wire • 06/01/21
Precision BioSciences to Participate in the Jefferies Virtual Healthcare ConferenceBusiness Wire • 05/26/21
Precision BioSciences' CD-19 CAR T Therapy Shows Response Rate Of 77% In Lymphoma TrialBenzinga • 05/20/21
Precision BioSciences to Present Data from its First Generation CD19 Allogeneic CAR T Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 American Society of Clinical Oncology MeetingBusiness Wire • 05/19/21
Precision BioSciences Reports First Quarter and 2021 Financial Results and Provides Business UpdateBusiness Wire • 05/13/21
Precision BioSciences Shares Move Higher As ARCUS Platform Shows Promising Gene Editing Approach For Transthyretin AmyloidosisBenzinga • 05/11/21
New Preclinical Data Presented at the 2021 American Society of Genetic & Cell Therapy Annual Meeting Highlights Precision BioSciences' ARCUS In Vivo Genome EditingBusiness Wire • 05/11/21
Precision BioSciences to Report First Quarter 2021 Financial Results on May 13, 2021Business Wire • 05/06/21
Precision BioSciences Announces Paper Presentation at the Association for Research in Vision and Ophthalmology 2021 Annual MeetingBusiness Wire • 05/03/21
Precision BioSciences Announces Poster Presentation at the Upcoming American Society of Gene & Cell Therapy Annual MeetingBusiness Wire • 04/27/21
Precision BioSciences Appoints Renowned Hematologist Alan List, M.D. as Chief Medical OfficerBusiness Wire • 04/15/21
Precision BioSciences Reacquires Global Rights to its Allogeneic CAR T ProgramsBusiness Wire • 04/15/21
Precision BioSciences to Participate in the Truist Securities 2021 Life Sciences Virtual SeriesBusiness Wire • 04/09/21
Precision BioSciences to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease DayGlobeNewsWire • 03/29/21
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 03/18/21